How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,619 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Belimumab for treating active autoantibody-positive systemic lupus erythematosus

Belimumab for treating active autoantibody-positive systemic lupus erythematosus Belimumab for treating activ Belimumab for treating active e autoantibody-positiv autoantibody-positive systemic lupus e systemic lupus erythematosus erythematosus T echnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

22. Guideline for the management of adults with Systemic Lupus Erythematosus Full Text available with Trip Pro

Guideline for the management of adults with Systemic Lupus Erythematosus We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults | Rheumatology | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input (...) Article Navigation Close mobile search navigation Article navigation January 2018 Article Contents Article Navigation The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults Caroline Gordon Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham,Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust,Rheumatology Department, University

2017 British Society for Rheumatology

23. Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study. Full Text available with Trip Pro

Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study. Cardiovascular disease is common in patients with systemic lupus erythematosis (SLE) and lupus nephritis (LN). Up to 80% of children with SLE develop kidney disease, which is also associated with increased risk for cardiovascular disease and death compared to those without renal involvement. Hepcidin is an iron-regulatory protein which may contribute to atherosclerosis

2019 PLoS ONE

24. Severe vaso-occlusive lupus retinopathy in the early stage of a pediatric patient with systemic lupus erythematosus: a case report. Full Text available with Trip Pro

Severe vaso-occlusive lupus retinopathy in the early stage of a pediatric patient with systemic lupus erythematosus: a case report. Systemic lupus erythematosus (SLE) is a multisystem, chronic, autoimmune disease which can affect any organ system including the eye. About one-third of the patients can be diagnosed with SLE-related eye involvement which is usually indicative of disease activity. Retinopathy is one of the most vision-threatening complications that can be associated (...) with the disease.An 11-year-old girl was hospitalized with complains of repeated swelling and pain in her extremities for 1 month, chest pain for 24 days, rash for 5 days and proteinuria for 1 day. On the morning of her fourth day in hospital, she suddenly complained of sudden, painless vision loss in the left eye. The ophthalmologist found that she had obstruction of central retinal vein and artery with diffuse retinal hemorrhages and macular edema.The patient was diagnosed with systemic lupus erythematosus

2020 Medicine

25. Impact of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto Lupus Clinic Cohort. (Abstract)

Impact of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto Lupus Clinic Cohort. To examine the role of disease activity on organ damage over 5 years in patients with active systemic lupus erythematosus (SLE) despite standard of care.This analysis of the University of Toronto Lupus Clinic cohort assessed organ damage (measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) in patients

2020 Journal of Rheumatology

26. Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. Full Text available with Trip Pro

Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. An often-neglected subset of patients with systemic lupus erythematosus (SLE) is those with secondary Sjögren syndrome (SLE-sSS). Further, primary SS overlaps and can be difficult to delineate from SLE. To shed light on the SLE-sSS subset, we investigated a large and well-characterized SLE cohort, comparing patients with SLE-sSS and SLE patients without SS (SLE-nonsSS) and controls.We (...) 10], total IgG, anti-SSA/Ro52, anti-SSA/Ro60, anti-SSB/La antibodies, and rheumatoid factor (IgM and IgA) were higher in the SLE-sSS group (p < 0.05 for all comparisons).The frequency of SLE-sSS increased with age and affected roughly one-quarter of all patients with SLE. Despite less internal organ involvement, a systemic inflammatory state with high levels of proinflammatory cytokines is present in the SLE-sSS subgroup. This is a novel observation that may affect future understanding

2020 Journal of Rheumatology

27. Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept Full Text available with Trip Pro

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept 30167444 2019 02 26 2352-5126 4 7 2018 Aug JAAD case reports JAAD Case Rep Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. 698-700 10.1016/j.jdcr.2018.03.008 Tarazi Meera M Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania. Department of Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania (...) School of Medicine, Philadelphia, Pennsylvania. eng Case Reports 2018 08 16 United States JAAD Case Rep 101665210 2352-5126 ANA, antinuclear antibodies CLE, cutaneous lupus erythematosus CTLA-4, cytotoxic T-lymphocyte–associated antigen-4 HCQ, hydroxychloroquine RA, rheumatoid arthritis SCLE, subacute cutaneous lupus erythematosus SLE, systemic lupus erythematosus abatacept drug-induced lupus erythematosus subacute cutaneous lupus erythematosus systemic lupus erythematosus 2018 9 1 6 0 2018 9 1 6 0

2018 JAAD Case Reports

28. Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus Full Text available with Trip Pro

Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus Previous studies demonstrated associations between reduced serum 25-hydroxyvitamin D (25OHD), inflammation and disease activity in paediatric systemic lupus erythematosus (pSLE). The goal of this study was to assess parathyroid hormone (PTH (...) ) in its relationship to vitamin D and inflammation, as well as to better understand the role of human cathelicidin (LL-37) in pSLE.Frozen serum samples collected at baseline of the Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study were assayed to determine 25OHD, PTH and LL-37 levels. Pearson's correlations and Χ2 tests were used to evaluate the relationships between 25OHD, PTH, LL-37, inflammation, disease activity and infection using baseline values collected as part

2018 Lupus science & medicine

29. Lupus erythematosus panniculitis in a 10-year-old female child with severe systemic lupus erythematosus: A case report. Full Text available with Trip Pro

Lupus erythematosus panniculitis in a 10-year-old female child with severe systemic lupus erythematosus: A case report. Lupus erythematosus panniculitis (LEP) is a rare subset of lupus erythematosus. The incidence of LEP in systemic lupus erythematosus (SLE) ranges from 2% to 5%. In the previous literature, most LEP patients were women aged from 20 to 60 years, while pediatric cases were rare, all of whom appeared on their own without SLE.A rare LEP in a 10-year-old female child with severe SLE

2018 Medicine

30. Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. Full Text available with Trip Pro

Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. There is a wide range in the reported prevalences of depression in patients with systemic lupus erythematosus (SLE), while the prevalence of depression in patients with cutaneous lupus erythematosus (CLE) remains severely understudied.To examine whether patients with SLE or CLE have an increased risk of depression.In this nationwide observational cohort (...) antidepressant use.A total of 3489 patients with lupus erythematosus were followed for 23 373 person-years. Compared with the general population, the adjusted hazard ratios (HRs) of depression were 2·07 [95% confidence interval (CI) 1·55-2·75] and 2·22 (95% CI 1·77-2·77) for patients with CLE and SLE, respectively; for hospitalization owing to depression at a department of psychiatry HRs were 2·63 (95% CI 0·80-8·67) and 3·52 (95% CI 1·53-8·11) for patients with CLE and SLE, respectively. The adjusted HRs

2018 British Journal of Dermatology

31. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. (Abstract)

Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Although pregnancy in systemic lupus erythematosus (SLE) carries a high risk for mother and fetus, outcomes may be improving.To assess nationwide trends and disparities in maternal and fetal complications among pregnant women with SLE.Retrospective cohort study.United States, 1998 to 2015.Adult pregnant women with and without SLE who had hospitalizations

2019 Annals of Internal Medicine

32. Systemic lupus erythematosus: oral mycophenolate

Systemic lupus erythematosus: oral mycophenolate Systemic lupus erythematosus: or Systemic lupus erythematosus: oral al m my ycophenolate cophenolate Evidence summary Published: 18 November 2014 nice.org.uk/guidance/esuom36 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in November 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites (...) -renal systemic lupus erythematosus mainly come from observational studies; further RCTs assessing the efficacy and safety of mycophenolate in people with non-renal systemic lupus erythematosus are needed. Regulatory status: Regulatory status: Off-label. This topic was prioritised because there was a high volume of requests from the NHS. Immunosuppressants such as mycophenolate are widely used in people with systemic lupus erythematosus, but not all are specifically licensed for this indication. ©

2014 National Institute for Health and Clinical Excellence - Advice

33. Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus (Abstract)

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemic lupus erythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE.This cross (...) -sectional study included 276 patients with SLE. These indices were measured: lipid profile, Systematic COronary Risk Evaluation (SCORE) risk calculation, and disease activity (SLE Disease Activity Index), severity (Katz), and damage [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index]. Carotid plaques were assessed by US. A multivariable regression analysis, adjusted for classic CV-related factors, was performed to evaluate how risk reclassification

2019 EvidenceUpdates

34. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial Full Text available with Trip Pro

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy.A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients (...) response rates were 55.17% and 30.00% for IL-2 and placebo, respectively (p=0.052). At week 24, the SRI-4 response rate of IL-2 group was 65.52%, compared with 36.67% of the placebo group (p=0.027). The primary endpoint was not met at week 12. Low-dose IL-2 treatment resulted in 53.85% (7/13) complete remission in patients with lupus nephritis, compared with 16.67% (2/12) in the placebo group (p=0.036). No serious infection was observed in the IL-2 group, but two in placebo group. Besides expansion

2019 EvidenceUpdates

35. Novel paradigms in systemic lupus erythematosus. (Abstract)

Novel paradigms in systemic lupus erythematosus. The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigators. Although the outlook for patients with SLE has greatly improved, many unmet needs remain, chief of which is the development of safer and more efficacious therapies. To develop innovative therapies, a far better understanding of SLE pathogenesis as it relates to the array (...) of clinical phenotypes is needed. Additionally, to efficiently achieve these goals, the lupus community needs to refine existing clinical research tools and better adapt them to overcome the obstacles created by the heterogeneity of manifestations. Here, we review progress towards the ultimate goal of safely reducing disease activity and preventing damage accrual and death. We discuss the new classification criteria from the European League Against Rheumatism and American College of Rheumatology, novel

2019 Lancet

36. Management strategies and future directions for systemic lupus erythematosus in adults. (Abstract)

Management strategies and future directions for systemic lupus erythematosus in adults. Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of self-tolerance and formation of nuclear autoantigens and immune complexes resulting in inflammation of multiple organs. The clinical presentation of SLE is heterogeneous, can involve one or more organs, including the skin, kidneys, joints, and nervous system, and take a chronic or relapsing and remitting disease course

2019 Lancet

37. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study (Abstract)

Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study We conducted this nationwide population-based study in Taiwan to investigate whether there is a bidirectional relationship between SLE and non-Hodgkin's lymphoma (NHL).Using the National Health Insurance Research Database of Taiwan, we identified 16 417 patients with new-onset SLE without previous cancer and 25 069 patients with new-onset NHL without previous SLE

2019 EvidenceUpdates

38. Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus Full Text available with Trip Pro

Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus Objective Neuropsychiatric systemic lupus erythematosus (NPSLE) is a manifestation of systemic lupus erythematosus (SLE). Central nervous system (CNS) infection is a consequence of intensive immunosuppressive therapy that patients with SLE might undergo. This study aimed to compare the differences between NPSLE and CNS infections in patients

2017 The Journal of international medical research

39. Aortic aneurysm and dissection in systemic lupus erythematosus-pathophysiologic and therapeutic considerations Full Text available with Trip Pro

Aortic aneurysm and dissection in systemic lupus erythematosus-pathophysiologic and therapeutic considerations 30071928 2018 11 14 2147-9720 5 3 2018 Sep European journal of rheumatology Eur J Rheumatol Aortic aneurysm and dissection in systemic lupus erythematosus-pathophysiologic and therapeutic considerations. 209-211 10.5152/eurjrheum.2018.17125 Kounis Nicholas G NG http://orcid.org/0000-0002-9751-6710 Department of Cardiology, University of Patras Medical School, Achaia, Greece. Koniari (...) Cardiothorac Surg. 2017 Oct 1;52(4):810-817 28402522 Lupus. 2016 Aug;25(9):959-63 26811371 Rev Port Cardiol. 2015 May;34(5):369-70 25935072 Vasc Endovascular Surg. 2016 Nov;50(8):571-574 28081690 Aorta (Stamford). 2013 Dec 01;1(6):259-67 26798703 Oncotarget. 2017 Feb 28;8(9):14283-14293 28179581 Lupus. 2014 Jun;23(7):665-71 24554710 Cardiovasc Res. 2017 Sep 1;113(11):1364-1375 28582477 Trends Cardiovasc Med. 2012 Aug;22(6):150-5 22902093 Eur J Rheumatol. 2017 Jun;4(2):133-135 28638687 Biomed Res Int

2018 European journal of rheumatology

40. Evidence of a distinct group of Black African patients with systemic lupus erythematosus Full Text available with Trip Pro

Evidence of a distinct group of Black African patients with systemic lupus erythematosus The autoimmune disease systemic lupus erythematosus (SLE) occurs more frequently in patients of African descent with high morbidity and mortality. Current SLE diagnostic criteria including antinuclear antibody (ANA) reactivity are derived largely from non-African populations. This study characterises ANA reactivity patterns and relates them to SLE clinical presentation in Black African patients.Sera from

2018 BMJ global health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>